New drug for targeted therapy for lung cancer

Targeted therapy is a revolutionary approach to the treatment of many types of cancer. It improves the survival rate in patients whose tumors are destroyed by different drugs for genetic mutations. The industry is growing rapidly and a new targeted lung cancer drug may soon become available. A European regulatory body will consider Merck's tepotinib for use in a specific type of this tumor.

Tepotinib is an oral drug that has shown promising results in a key VISION Phase II study. It is a highly selective MET inhibitor administered once a day. Tepotinib is developed for the treatment of metastatic non-small cell lung cancer (NSCLC) in adult patients with a mutation of the mesenchymal-epithelial transition factor (METEX14), which carries exon 14 (METEX14). According to Merck, this genotype occurs in 3-4% of NSCLC cases and is associated with aggressive tumor behavior.

Source: PHARMA TIMES